CPT code 87633 denotes a molecular diagnostic assay that detects 12–25 respiratory viruses using amplified nucleic acid probe techniques, frequently employing multiplex reverse transcription. This code matters nationally because comprehensive respiratory viral panels support clinical diagnosis, infection control, and public health surveillance, particularly during respiratory virus seasons and outbreaks. Accurate coding affects lab billing, payer coverage determinations, and claims processing for complex molecular tests.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for broad respiratory viral panels, typical service settings where the test is performed, and common payer considerations. The content covers expected benchmarks and policy-relevant points such as payer coverage patterns for multiplex molecular assays, coding clarity for high-target panels, and potential implications for laboratory billing workflows.

This publication is intended to inform laboratory managers, coding professionals, and policy analysts about CPT code 87633 — what it represents, where it is typically performed, and the payer landscape relevant to nationally deployed respiratory viral molecular testing. Data not available in the input are noted where applicable.